Rosuvastatin positively changes nerve electrophysiology in diabetic rats

Tarhzaoui, K.; Valensi, P.; Léger, Gérard; Cohen-Boulakia, F; Lestrade, R.; Béhar, A.

doi:10.1002/dmrr.920

Cited by 9 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data indicated an extent of renoprotection provided by the applied regimens and similar to Tarhzaoui et al [48] who reported that in diabetic rats RSU prevented the increase in peripheral capillary filtration of albumin and induced a decrease in blood pressure. The beneficial effect of RSU on endothelial function does not seem to result from blood pressure reduction nor lipid lowering effects.…”

Section: Tablesupporting

confidence: 89%

Effect of resveratrol and rosuvastatin on experimental diabetic nephropathy in rats

Hussein

Mahfouz

2016

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Section: Tablesupporting

confidence: 89%

Effect of resveratrol and rosuvastatin on experimental diabetic nephropathy in rats

Hussein

Mahfouz

2016

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

“…Another potential explanation is direct effects on airway neuronal cells or their conductive function (Tarhzaoui et al. ), thereby affecting the neural contribution to bronchoconstriction. Of note, different agonists or pharmacologic agents can induce changes in both AHR and AHS.…”

Section: Discussionmentioning

confidence: 99%

Intratracheal instillation of pravastatin for the treatment of murine allergic asthma: a lung-targeted approach to deliver statins

et al. 2015

View full text Add to dashboard Cite

Systemic treatment with statins mitigates allergic airway inflammation, TH2 cytokine production, epithelial mucus production, and airway hyperreactivity (AHR) in murine models of asthma. We hypothesized that pravastatin delivered intratracheally would be quantifiable in lung tissues using mass spectrometry, achieve high drug concentrations in the lung with minimal systemic absorption, and mitigate airway inflammation and structural changes induced by ovalbumin. Male BALB/c mice were sensitized to ovalbumin (OVA) over 4 weeks, then exposed to 1% OVA aerosol or filtered air (FA) over 2 weeks. Mice received intratracheal instillations of pravastatin before and after each OVA exposure (30 mg/kg). Ultra performance liquid chromatography – mass spectrometry was used to quantify plasma, lung, and bronchoalveolar lavage fluid (BALF) pravastatin concentration. Pravastatin was quantifiable in mouse plasma, lung tissue, and BALF (BALF > lung > plasma for OVA and FA groups). At these concentrations pravastatin inhibited airway goblet cell hyperplasia/metaplasia, and reduced BALF levels of cytokines TNFα and KC, but did not reduce BALF total leukocyte or eosinophil cell counts. While pravastatin did not mitigate AHR, it did inhibit airway hypersensitivity (AHS). In this proof-of-principle study, using novel mass spectrometry methods we show that pravastatin is quantifiable in tissues, achieves high levels in mouse lungs with minimal systemic absorption, and mitigates some pathological features of allergic asthma. Inhaled pravastatin may be beneficial for the treatment of asthma by having direct airway effects independent of a potent anti-inflammatory effect. Statins with greater lipophilicity may achieve better anti-inflammatory effects warranting further research.

show abstract

“…Simvastatin has been shown to promote neuritic outgrowth on myelin substrates that would normally prevent regeneration and growth of axons (Holmberg et al 2006 ) . Statins also have bene fi cial effects on nerve conduction and generation of neuroblasts in neurodegenerative models (Tarhzaoui et al 2009 ;Chen et al 2009 ). In vitro studies have demonstrated the ability of lipophilic statins to in fl uence cellular processes in human and rodent OPCs that have been implicated in the remyelination process Paintlia et al 2005 ) .…”

Section: Statinsmentioning

confidence: 99%

Effects of Current Medical Therapies on Reparative and Neuroprotective Functions in Multiple Sclerosis

Antel

Miron

2012

Myelin Repair and Neuroprotection in Multiple Sclerosis

View full text Add to dashboard Cite

Multiple sclerosis (MS) is most frequently clinically characterized by an initial relapsing-remitting phase that evolves into a secondary progressive course; these phases can also be ongoing concurrently. Each of these clinical disease aspects re fl ects distinctive pathologic substrates, each of which may require its own therapeutic strategies. The pathologic correlate of clinical relapses is the development of new demyelinating lesions within the CNS that feature an in fl ammatory in fi ltrate comprised of cells of the adaptive (lymphocytes) and innate (myeloid cells) systems that have transgressed the blood-brain barrier (BBB) and/or the subarachnoid space/ brain barrier (Kivisakk et al. 2003 ) . Axonal transections are a further feature of the acute lesions (Trapp et al. 1998 ) . Magnetic resonance imaging (MRI) studies indicate that multiple such lesions can occur without apparent clinical symptoms (Engell 1989 ). Recovery from relapses re fl ects the combined effects of multiple factors including resolution of in fl ammation, axonal adaptation to demyelination, remyelination, and cerebral reorganization. The pathologic correlates of the later progressive disease phase are even more complex involving changes both within initial

show abstract

Rosuvastatin positively changes nerve electrophysiology in diabetic rats

Abstract: This study shows that: 1.rosuvastatin exerts a beneficial effect on the conduction of the fastest sensory fibres;2.these effects are independent of blood pressure and lipid changes.

Cited by 9 publications

References 28 publications

Effect of resveratrol and rosuvastatin on experimental diabetic nephropathy in rats

Effect of resveratrol and rosuvastatin on experimental diabetic nephropathy in rats

Intratracheal instillation of pravastatin for the treatment of murine allergic asthma: a lung-targeted approach to deliver statins

Effects of Current Medical Therapies on Reparative and Neuroprotective Functions in Multiple Sclerosis

Contact Info

Product

Resources

About